XML 30 R16.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Equity Based Compensation | 12 Months Ended
--- | ---
Dec. 30, 2017
Equity Based Compensation [Abstract] |
Equity Based Compensation | NOTE J – EQUITY-BASED COMPENSATION ﻿ Equity-based compensation expense was $11,081, $16,542, and $15,482 for fiscal years 2015, 2016, and 2017, respectively. The related tax benefit for these periods was $3,766, $5,540, and $5,144, respectively. ﻿ The following table shows the remaining unrecognized compensation expense on a pre-tax basis for all types of unvested equity awards outstanding as of December 30, 2017. This table does not include an estimate for future grants that may be issued. ﻿ ﻿ ﻿
﻿ |  |
﻿ |  |
﻿2018 |  | $ 14,071
﻿2019 |  | 10,393
﻿2020 |  | 4,597
﻿2021 |  | 2,680
﻿ |  | $ 31,741
﻿ |  |
﻿The cost above is expected to be recognized over a weighted-average period of 2.87 years. |  |
﻿ |  |
﻿ The Company’s 2015 Equity Incentiv e Award Plan (the “2015 Plan”) allows for the grant of various equity awards including stock-settled stock appreciation rights, stock options, restricted stock units, deferred stock units, and other types of equity-based awards to the Company’s officers, key employees, and non-employee directors. Prior to the approval of the 2015 plan, the Company maintained a 2006 Equity Incentive Award Plan (the “2006” Plan”), which expired in April of 2016. The 2015 Plan replaced the 2006 Plan for all future grants, and no new awards have been granted under the 2006 Plan. ﻿ At the inception of the 2015 Plan, 13,839 awards had been granted under the 2006 Plan, of which 13,595 were stock-settled stock appreciation rights, 15 were stock options, and 229 were deferred stock units. Also, at the inception of the 2015 Plan, 2,551 awards had been forfeited. Under the 2015 Plan, 10,000 shares have been authorized. As of December 30, 2017, 2,873 awards had been granted under the 2015 Plan, of which 2,752 were stock-settled stock appreciation rights, and 121 were restricted stock awards. Also, as of December 30, 2017, a total of 769 awards had been forfeited and added back to the number of shares available for issuance under the 2015 Plan. ﻿ Stock-Settled Stock Appreciation Rights ﻿ The Company uses the Black-Scholes option pricing model to estimate the fair value of its stock-settled stock appreciation right s. Beginning in 2015, certain new grants of stock-settled stock appreciation rights became subject to a mandatory post-vesting holding requirement of 10% of the shares derived upon exercise for the sooner of five years following the exercise or at such time the grantee no longer qualifies as a participant under the Plan. As a result of this requirement, the Company has included an illiquidity discount in the fair value calculation of these awards. The weighted-average fair value, net of illiquidity discount, of stock-settled stock appreciation rights that was $23.50, and $22.99, granted in 2015 and 2016, respectively. There were no stock-settled stock appreciation rights granted in 2017. ﻿ Stock-settled stock appreciation rights granted to officers and key employees upon hire or promotion to such a position generally vest 20% each year on the anniversary of the grant date and expire five and one-half years from the date of grant. Awards granted as a supplement to existing equity awards held by officers and key employees will generally vest 50% each year beginning on the first grant date anniversary following the final vesting of previous grants. The expiration of these supplemental awards is generally within 12 months following the last vest date of such award. There were no stock-settled stock appreciation rights granted in 2017. ﻿ Following is a table that includes the weighted-average assumptions that the Company used to calculate fair value of stock-settled stock appreciation rights that were granted during the periods indicated. NOTE J – EQUITY-BASED COMPENSATION - CONTINUED ﻿ ﻿ ﻿ ﻿
﻿ |  |  |  |  |  |  |  |
﻿ |  |  |  |  |  |  |  |
﻿ |  | Year ended |  |
﻿ |  |  |  |  |  |  |  |
﻿ |  | 2015 |  | 2016 |  | 2017 |  |
﻿ |  |  |  |  |  |  |  |
﻿Expected volatility (1) |  | 44.0% |  | 47.5% |  | N/A |  |
﻿Risk-free interest rate (2) |  | 1.3% |  | 1.1% |  | N/A |  |
﻿Expected life (3) |  | 3.8 yrs. |  | 3.7 yrs. |  | N/A |  |
﻿Expected dividend yield (4) |  | 0.0% |  | 0.0% |  | N/A |  |
﻿Weighted-average exercise price (5) |  | $67.71 |  | $63.16 |  | N/A |  |
﻿ |  |  |  |  |  |  |  |
﻿(1) The Company utilizes historical volatility of the trading price of its common stock. |
﻿(2) Risk-free interest rate is based on the U.S. Treasury yield curve with respect to the expected life of the award. |
﻿(3) Depending upon the terms of the award, one of two methods will be used to calculate expected life: |
﻿ (i) a weighted-average that includes historical settlement data of the Company’s equity awards and a |
﻿ hypothetical holding period, or (ii) the simplified method. |
﻿(4) The Company historically has not paid and currently has no plan to pay dividends. |  |
﻿(5) Exercise price is the closing price of the Company's common stock on the date of grant. |  |
﻿ |  |
﻿ A summary of the Company’s stock-settled stock appreciation right activity is as follows: ﻿
﻿ |  |  |  |  |  |  |  |  |
﻿ |  | Shares |  | Weighted-average exercise price |  | Weighted-average remaining contractual term |  | Aggregate intrinsic value* |
﻿Outstanding at December 31, 2016 |  | 3,391 |  | $ 54.69 |  | 3.1 |  | $ 36,169 |
﻿Granted |  | - |  | - |  |  |  |  |
﻿Exercised |  | (884) |  | 33.63 |  |  |  |  |
﻿Forfeited |  | (181) |  | 55.78 |  |  |  |  |
﻿Expired |  | (36) |  | 65.26 |  |  |  |  |
﻿ |  |  |  |  |  |  |  |  |
﻿Outstanding at December 30, 2017 |  | 2,290 |  | $ 62.49 |  | 2.6 |  | $ 26,703 |
﻿ |  |  |  |  |  |  |  |  |
﻿Exercisable at December 30, 2017 |  | 420 |  | $ 53.12 |  | 2.1 |  | $ 8,782 |
﻿ |  |  |  |  |  |  |  |  |
﻿ |
﻿ ﻿ * Aggregate intrinsic value is defined as the difference between the current market value at the reporting date (the closing price of the Company's common stock on the last trading day of the period) and the exercise price of awards that were in-the-money. The closing price of the Company's common stock at December 31, 2016, and December 30, 2017, was $61.20 and $74.05, respectively. ﻿ The total intrinsic value of stock-settled stock appreciation rights exercised was $41,548 in 2015, $38,198 in 2016, and $25,424 in 2017. The total fair value of stock-settled stock appreciation rights that vested was $7,184, $11,481, and $14,126, for the years ended 2015, 2016, and 2017 respectively. ﻿ During the year ended December 30, 2017, certain employees elected to receive a net amount of shares upon the exercise of stock-settled stock appreciation rights in order to satisfy the Company’s tax withholding obligation. This resulted in a $316 reduction to additional paid-in capital. ﻿ NOTE J – EQUITY-BASED COMPENSATION - CONTINUED Restricted Stock Awards ﻿ Restricted stock awards include restricted stock units granted to the Company’s officers and key employees, and deferred stock units granted to non-employee directors. Restricted stock units are granted to officers and key employees upon hire or promotion to such a position, or annually for existing participants, and generally vest 25% each year on the anniversary of the grant date. Awards of deferred stock units granted to non-employee directors generally vest 25% each quarter, commencing on the first vest date anniversary following the final vesting of the previous award. The fair value of restricted stock awards is determined based on the Company’s closing stock price on the date of grant. Restricted stock awards are full-value shares at the date of grant, vesting over the periods of service, and do not have expiration dates. ﻿ A summary of the Company’s restricted stock unit activity is as follows: ﻿
﻿ |  |  |  |
﻿ |  | Shares |  | Weighted-average grant date fair value
﻿Outstanding at December 31, 2016 |  | - |  | $ -
﻿Granted |  | 92 |  | 59.42
﻿Vested |  | - |  | -
﻿Forfeited |  | - |  | -
﻿ |  |  |  |
﻿Outstanding at December 30, 2017 |  | 92 |  | $ 59.42
﻿ |  |  |  |
﻿ A summary of the Company’s deferred stock unit activity is as follows: ﻿
﻿ |  |  |  |
﻿ |  | Shares |  | Weighted-average grant date fair value
﻿Nonvested at December 31, 2016 |  | 5 |  | $ 61.60
﻿Granted |  | 8 |  | 58.00
﻿Vested |  | (10) |  | 59.14
﻿Forfeited |  | - |  | -
﻿ |  |  |  |
﻿Nonvested at December 30, 2017 |  | 3 |  | $ 60.24
﻿ |  |  |  |
﻿ The number of deferred stock units vested and unreleased totaled 14 and 24 as of December 31, 2016 and December 30, 2017, respectively. ﻿ The total fair value of deferred stock units that vested was $0, $962, and $638, for the years ended 2015, 2016, and 2017 respectively. There were no restricted stock units that vested during these years.

X
- Definition The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -URI http://asc.fasb.org/subtopic&trid=2208855 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration